Osteoporotic fragility fractures Musculoskeletal Diseases
Conditions
Interventions
The study will be completed in 3 stages. Stage 1A will update a systematic review to inform which regimens are most effective at reducing fractures and provide the best value for money. Stage 1B will
Sponsors
Nottingham University Hospitals NHS Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adults over the age of 18 with the ability to give informed consent Participants will need to come from one of the following stakeholder groups: 2. GPs 3. Patients who started on oral bisphosphonates within the last 24 months for prevention of fragility fractures 4. Secondary care specialist clinicians (nurses, consultants) involved in the treatment of osteoporosis 5. Patients receiving hospital based (intravenous) bisphosphonate treatments for prevention of fragility fractures who began treatment within the last 24 months 6. Clinical academics involved in osteoporosis research 7. Specialist clinicians (nurses, consultants) from the osteoporosis service in Nottingham and Sheffield with insight into alternate bisphosphonate treatments 8. Patients receiving alternate bisphosphonate treatments for prevention of fragility fractures who began treatment within the last 24 months 9. Commissioners involved in osteoporosis services
Exclusion criteria
Exclusion criteria: 1. Patients who take bisphosphonate medicines for reasons other than osteoporosis or osteopenia, including patients with an active cancer, primary hyperparathyroidism and Paget’s disease 2. Considered to be near to end of life
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Views, experiences and preferences of patients, clinicians and researchers regarding different bisphosphonate treatment regimens collected through conduction and analysis of semi-structured interviews. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Effectiveness of different bisphosphonate regimens in preventing fragility fractures in adults by analysis of published literature by systematic review 2. Cost-effectiveness of different bisphosphonate regimens in preventing fragility fractures in adults using a health economic model on data of published literature identified by systematic review 3. Prioritised future research questions regarding the effectiveness and adherence profile of different bisphosphonate regimens in preventing fragility fractures in adults by stakeholder engagement workshops using the James Lind methodology | — |
Countries
England, United Kingdom
Outcome results
None listed